

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Investor News

NeuroSearch to present at Cowen's 27th Annual US Health Care Conference in Boston

NeuroSearch (NEUR) will present at Cowen's 27th Annual Health Care Conference to be held from Monday 12 to Thursday 15 March at The Boston Marriott Copley Place Hotel, 110 Huntington Avenue, Boston, USA.

The presentation will be held by Flemming Pedersen, CEO, and is scheduled for

Tuesday 13 March at 3:15 - 3:50 pm

The presentation will be followed by a breakout session at 4:00 - 4:35 pm.

A PowerPoint version of the presentation will be accessible on our website www.neurosearch.com just prior to the presentation at the conference.

Contact: Hanne Leth Hillman, Vice President, Director of Investor Relations and Corporate Communications

Phone: +45 4460 8212 or +45 4017 5103

NeuroSearch is a Scandinavian biopharmaceutical company listed on the Copenhagen Stock Exchange (NEUR). Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and transporters. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. Nine drug programmes are in clinical development: ACR16 for the treatment of Huntington's disease (under preparation for Phase III), tesofensine for the treatment of obesity/type 2 diabetes (Phase II), NS2359 for the treatment of depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 for the treatment of epilepsy and pain (Phase II), ABT-894 for the treatment of ADHD (Phase II) and neuropathic pain (Phase I) in partnership with Abbott, ACR16 for the treatment of schizophrenia (Phase I) in partnership with Astellas, and ACR325 for the treatment of psychoses and bipolar disorder (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and has equity interests in several biotech companies.